Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 24231-24240 Newer>

The Motley Fool June 29, 2007 Ryan Fuhrmann	Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.
The Motley Fool June 29, 2007 Sham Gad	MSC Nails Another Quarter The industrial specialist performs well. But investors want to know -- is it cheap?
The Motley Fool June 29, 2007	KB Liquidates Assets: Fool by Numbers The home builder released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool June 29, 2007 Steven Mallas	Hef Builds a Mansion in China Macao should see excellent growth in its gambling industry over the next several years. This will increase tourism, and bode well for Playboy Mansion Macao. Investors, take note.
The Motley Fool June 29, 2007	Hope for Chistopher & Banks: Fool by Numbers The clothier released first-quarter 2008 earnings results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool June 29, 2007 Timothy M. Otte	Christopher & Banks Stumbles, Again The women's apparel retailer reports a lower than expected first-quarter, and issues a second-quarter warning. Some might view the stock as a bargain, down nearly 50% compared to last year.
The Motley Fool June 29, 2007 Ryan Fuhrmann	Soap Dispenser Half-Empty at Bed Bath Bed Bath & Beyond is slowing down, but by how much? Investors appear to be exiting shares in droves, but the jury is still out on whether shoppers are following a similar path.
The Motley Fool June 29, 2007 Matt Koppenheffer	Your Move, Kravis Will the lackluster performance of Blackstone hamper other private equity offerings?
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
<Older 24231-24240 Newer> Return to current articles.